Overview
- Researchers at a U.S.‑funded Panama facility are awaiting local biosecurity approval to move NovoFly from the lab into confined outdoor mesh‑cage tests, with larger ranch releases planned about nine to 12 weeks later using 50,000 flies every few days.
- NovoFly is engineered so only male offspring survive, which would effectively double the number of sterile males available for release because current production now yields both sexes.
- Current sterile‑fly output from the Panama plant is roughly 100 million insects per week while experts estimate about 400–500 million sterile males per week are needed to push the outbreak back toward the Darién Gap, leaving a major capacity shortfall.
- Scientists and officials warn NovoFly’s flight ability, mating competitiveness and large‑scale rearing must be proven in trials and regulators must clear the strain, and they caution that introducing the new line into Panama production could risk disrupting existing output.
- Countries are coordinating responses with Mexico signaling support and possible local NovoFly production by year‑end, the U.S. planning a new Texas facility, and officials saying even a successful NovoFly rollout will take months to ease livestock impacts and trade controls.